Logo Logo Logo Logo Logo
  • Home
  • Company
    • Company Focus
    • Leadership Team
    • Scientific Advisory Board
    • Calypso Biotech Operations
    • Board of Directors
  • Science
  • Pipeline
  • Newsroom
  • Contact
  • Careers
  • Home
  • Company
    • Company Focus
    • Leadership Team
    • Scientific Advisory Board
    • Calypso Biotech Operations
    • Board of Directors
  • Science
  • Pipeline
  • Newsroom
  • Contact
  • Careers

20 February 2019: Calypso Biotech BV secures 20 Million EUR in Series A Financing and Strengthens Team to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases.

Posted at h in Press release

Click to see full press release...

Read More

19 February 2019: AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002

Posted at h in Press release

Click to see full press release...

Read More

31 March 2017: Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma

Posted at h in Press release
Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.
Read More

© Calypso Biotech 2018 – Legal disclaimer

We run statistic cookies to help us understand how visitors interact with our website by collecting and reporting information anonymously. By continuing to use our website you consent to cookies being used.YesPrivacy policy